{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T22:40:45Z","timestamp":1723329645094},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jdcr.2024.05.024","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T19:42:14Z","timestamp":1717011734000},"page":"51-55","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A case report of primary cutaneous diffuse large B-cell lymphoma in chronic myeloid leukemia after treatment with dasatinib"],"prefix":"10.1016","volume":"50","author":[{"given":"Yeon Joo","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joong Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2024.05.024_bib1","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jdcr.2024.05.024_bib2","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/sj.leu.2403874","article-title":"Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia","volume":"19","author":"Roy","year":"2005","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jdcr.2024.05.024_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s12185-019-02620-2","article-title":"Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors","volume":"109","author":"Sasaki","year":"2019","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.jdcr.2024.05.024_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1158\/1055-9965.EPI-06-1069","article-title":"Non-Hodgkin lymphoma secondary to cancer chemotherapy","volume":"16","author":"Krishnan","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jdcr.2024.05.024_bib5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/ccr3.3770","article-title":"High-grade B-cell lymphoma developed during the treatment of chronic myeloid leukemia with Bosutinib","volume":"9","author":"Takakuwa","year":"2021","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jdcr.2024.05.024_bib6","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/aje\/kwq262","article-title":"Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study","volume":"172","author":"Rebora","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jdcr.2024.05.024_bib7","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","article-title":"Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Fabarius","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jdcr.2024.05.024_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ajh.20025","article-title":"Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature","volume":"75","author":"Rodler","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jdcr.2024.05.024_bib9","first-page":"241","article-title":"Extranodal marginal zone B-cell lymphoma arising in chronic myeloid leukaemia successfully treated with tyrosine kinase inhibitor: a case report","volume":"20","author":"Mihaylov","year":"2016","journal-title":"Hippokratia"},{"key":"10.1016\/j.jdcr.2024.05.024_bib10","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s12185-017-2378-y","article-title":"Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia","volume":"107","author":"Fujiwara","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jdcr.2024.05.024_bib11","first-page":"74","article-title":"Hodgkin lymphoma in a case of chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"35","author":"Gajendra","year":"2019","journal-title":"Turk Patoloji Derg"},{"key":"10.1016\/j.jdcr.2024.05.024_bib12","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.2147\/OTT.S212838","article-title":"A case of primary gastric diffuse large B-cell lymphoma occurring in chronic myeloid leukemia","volume":"12","author":"Cai","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jdcr.2024.05.024_bib13","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1111\/bjh.16089","article-title":"Paediatric-type nodal follicular lymphoma in a child diagnosed with chronic myeloid leukaemia","volume":"186","author":"Dom\u00ednguez-Pinilla","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jdcr.2024.05.024_bib14","article-title":"Follicular lymphoma secondary to chronic myeloid leukemia during treatment with imatinib","volume":"14","author":"Geelani","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jdcr.2024.05.024_bib15","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2147\/OTT.S300320","article-title":"Hodgkin lymphoma as a secondary neoplasm during therapy for chronic myeloid leukaemia: case report and review of the literature","volume":"14","author":"Paczkowska","year":"2021","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jdcr.2024.05.024_bib16","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2016.20","article-title":"Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV","volume":"30","author":"Miranda","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jdcr.2024.05.024_bib17","first-page":"152","article-title":"HHV8-negative effusion-based large B cell lymphoma arising in chronic myeloid leukemia patients under dasatinib treatment: a report of two cases","volume":"10","author":"Fiori","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.jdcr.2024.05.024_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3960\/jslrt.22041","article-title":"Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia","volume":"63","author":"Suyama","year":"2023","journal-title":"J Clin Exp Hematop"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624002030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624002030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T22:00:51Z","timestamp":1723327251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512624002030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":18,"alternative-id":["S2352512624002030"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.05.024","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case report of primary cutaneous diffuse large B-cell lymphoma in chronic myeloid leukemia after treatment with dasatinib","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}